Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galecto Inc (GLTO)

Galecto Inc (GLTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,048
  • Shares Outstanding, K 27,113
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,350 K
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade GLTO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.14
  • Most Recent Earnings $-0.20 on 04/29/24
  • Next Earnings Date 07/29/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 61.94%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.39
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +24.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4600 +25.80%
on 07/02/24
0.6427 -9.96%
on 07/15/24
+0.0875 (+17.81%)
since 06/25/24
3-Month
0.4600 +25.80%
on 07/02/24
0.7400 -21.80%
on 05/03/24
-0.0902 (-13.48%)
since 04/25/24
52-Week
0.4600 +25.80%
on 07/02/24
3.7000 -84.36%
on 07/26/23
-2.4713 (-81.03%)
since 07/25/23

Most Recent Stories

More News
Nasdaq Futures Climb as Bond Yields Retreat From Decade Highs, Micron Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ23) are trending up +0.44% this morning as U.S. Treasury yields slipped from decade highs, while investors braced for a new round of economic data as well as an earnings...

NQZ23 : 16,530.23s (-0.07%)
CTAS : 763.18 (+1.21%)
AAPL : 220.47 (+0.88%)
GOOGL : 172.53 (-0.06%)
AMZN : 183.06 (+1.23%)
DKNG : 36.61 (+2.09%)
MU : 110.31 (+0.03%)
PAYX : 125.46 (+1.80%)
JEF : 56.92 (+4.25%)
HMB.S.DX : 165.600 (+0.98%)
COST : 827.84 (-0.36%)
CHPT : 2.1000 (+8.81%)
Galecto Reports Second Quarter Operating and Financial Results

BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 0.5787 (+4.27%)
Galecto to Participate at Jefferies Healthcare Conference

BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 0.5787 (+4.27%)
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses...

GLTO : 0.5787 (+4.27%)
Galecto Reports First Quarter Operating and Financial Results

BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...

GLTO : 0.5787 (+4.27%)
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2023...

GLTO : 0.5787 (+4.27%)
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously...

GLTO : 0.5787 (+4.27%)
Galecto Reports Financial Results for the Year Ended December 31, 2021

Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON, Feb. 17,...

GLTO : 0.5787 (+4.27%)
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides...

GLTO : 0.5787 (+4.27%)
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto...

GLTO : 0.5787 (+4.27%)

Business Summary

Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters...

See More

Key Turning Points

3rd Resistance Point 0.6165
2nd Resistance Point 0.6022
1st Resistance Point 0.5786
Last Price 0.5787
1st Support Level 0.5407
2nd Support Level 0.5264
3rd Support Level 0.5028

See More

52-Week High 3.7000
Fibonacci 61.8% 2.4623
Fibonacci 50% 2.0800
Fibonacci 38.2% 1.6977
Last Price 0.5787
52-Week Low 0.4600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar